The pharmacology of putative early-onset antidepressant strategies

European Neuropsychopharmacology

Volumn 13, Issue 2, 2003, Pages 57-66

  Blier, Pierre ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antidepressant; Depression; Mirtazapine; Noradrenaline; Onset of action; Pindolol; Serotonin; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOGENIC AMINE; BRAIN MONOAMINE; CITALOPRAM; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; NORADRENALIN; PINDOLOL; PROPRANOLOL; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

BLOOD BRAIN BARRIER; CELL LEVEL; CLINICAL TRIAL; DEPRESSION; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSPORT; FEEDBACK SYSTEM; GASTROINTESTINAL SYMPTOM; HUMAN; META ANALYSIS; NEUROTRANSMISSION; PRIORITY JOURNAL; REVIEW; SLEEP DISORDER;

EID: 0037338273     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(02)00173-6     Document Type: Review

References (80)

1. Béïque J.C., Lavoie N., de Montigny C., Debonnel G. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur. J. Pharmacol. 349:1998;129-132.
2. Béïque J.C., de Montigny C., Blier P., Debonnel G. Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. Synapse. 32:1999;198-211.
3. Benkert O., Grunder G., Wetzel H., Hackett D. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J. Psychiatr. Res. 30:1996;441-451.
4. Benkert O., Szegedi A., Kohnen R. Rapid onset of therapeutic action in major depression: a comparative trial of mirtazapine and paroxetine. J. Clin. Psychiatry. 69:2000;656-663.
5. Berman R.M., Anand A., Cappiello A., Miller H.L., Hu X.S., Oren D.A., Charney D.S. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol. Psychiatry. 45:1999;1170-1177.
6. Besson A., Haddjeri N., Blier P., de Montigny C. Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur. Neuropsychopharmacol. 10:2000;177-188.
7. Blier P., de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology. 21:(2S):1999;91-98.
8. Blier P., Dong J., Haddjeri N. Desensitization of the 5-HT1A autoreceptor by long-term mirtazapine treatment. American College of Neuropsychopharmacology 40th Annual Meeting, Waikoloa. Hawaii :2001.
9. Bolden-Watson C., Richelson E. Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 52:1983;1023-1029.
10. Bordet R., Thomas P., Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind placebo-controlled trial. Am. J. Psychiatry. 155:1998;1346-1351.
11. Clerc G.E., Ruimy P., Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int. Clin. Psychopharmacol. 9:1994;139-143.
12. Daly J.J., Prudic J., Devanand D.P., Nobler M.S., Lisanby S.H., Peyser S., Roose S.P., Sackeim H.A. ECT in bipolar and unipolar depression: differences in speed of response. Bipolar Disord. 3:2001;95-104.
13. de Boer T., Nefkens F., Van Helvoirt A., van Delft A.M. Differences in the modulation of noradrenergic and serotonergic transmission by the alpha-2-adrenoceptor antagonists mirtazapine, mianserin and idazoxan. J. Pharmacol. Exp. Ther. 277:1996;852-860.
14. de Boer T., Ruigt G., Berendsen H. The selective alpha-2-adrenoceptor agonist Org3770 (mirtazapine, Remeron) enhances noradrenergic and serotonergic neurotransmission. Hum. Psychopharmacol. 10:(Suppl. 2):1995;S107-S119.
15. de Boer T. The pharmacologic profile of mirtazapine. J. Clin. Psychiatry. 57:1996;19-25.
16. De Paula A., Omer L. Diclofensine (Ro 8-4650), a new psychoactive drug: its efficacy and safety in non-psychotic depression under double-blind placebo-controlled conditions. Curr. Ther. Res. 28:1980;837-844.
17. Debonnel G., Blier P., St-Andre E., Hebert C., de Montigny C. Comparison of the effect of low and high doses of venlafaxine on serotonin and norepinephrine reuptake processes in patients with major depression and healthy volunteers. Int. J. Neuropsychopharmacol. 1:(Suppl 1):1998;17.
18. Delgado P.L., Moreno F.A., Onate L., Gelenberg A.J. Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients. Int. J. Neuropsychopharmacol. 5:2002;63-66.
19. Dong J., Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology. 155:2001;52-57.
20. Entsuah R., Derivan A., Kikta D. Early onset of antidepressant action of venlafaxine: pattern analysis in intent-to-treat patients. Clin. Ther. 20:1998;517-526.
21. Gillin J.C. The sleep therapies of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry. 7:1983;351-364.
22. Goodnough D.B., Baker G.B. 5-Hydroxytryptamine2 and beta-adrenergic receptor regulation in rat brain following chronic treatment with desipramine and fluoxetine alone and in combination. J. Neurochem. 62:1994;2262-2268.
23. Guelfi J.D., White C., Hackett D., Guichoux J.Y., Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J. Clin. Psychiatry. 56:1995;450-458.
24. Haddjeri N., Blier P., de Montigny C. Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J. Pharmacol. Exp. Ther. 277:1996;861-871.
25. Haddjeri N., Blier P., de Montigny C. Effects of long-term treatment with the α2-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn-Schmiedeberg's Arch. Pharmacol. 355:1997;20-29.
26. Haddjeri N., de Montigny C., Blier P. Modulation of the firing activity of noradrenergic neurones in the rat locus coeruleus by the 5-hydroxytryptamine system. Br. J. Pharmacol. 120:1997;865-875.
27. Haddjeri N., Blier P. Effects of sustained (+/-) pindolol administration on serotonin neurotransmission in rats. J. Psychiatr. Neurosci. 25:2000;378-388.
28. Haddjeri N., Szabo S.T., de Montigny C., Blier P. Increased tonic activation of rat forebrain 5-HT(1A) receptors by lithium addition to antidepressant treatments. Neuropsychopharmacology. 22:2000;346-356.
29. Huitfeldt B., Montgomery S. Comparison between zimelidine and amitriptyline of efficacy and adverse symptoms. Acta Psychiatr. Scand. 68:(Suppl 308):1983;55-70.
30. Isaac M.T. Assessing the rate of onset of antidepressants: some methodological issues. Can. Coll. Neuropsychopharmacol. 24:2001;11.
31. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
32. Laska E., Meisner M.J. Nonparametric estimation and testing in a cure model. Biometrics. 48:1992;1223-1234.
33. Leinonen E., Skarstein J., Behnke K., Agren H., Helsdingen J.T. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int. Clin. Psychopharmacol. 14:1999;329-337.
34. Lejeune F., Audinot V., Gobert A., Rivet J.M., Spedding M., Millan M.J. Clozapine inhibits serotoninergic transmission by an action at alpha 1-adrenoceptors not at 5-HT1A receptors. Eur. J. Pharmacol. 260:1994;79-83.
35. Maes M., Vandoolaeghe E., Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J. Affect. Disord. 41:1996;201-210.
36. Maes M., Libbrecht I., Van Hunsel F., Campens D., Meltzer H.Y. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J. Clin. Psychopharmacol. 19:1999;177-182.
37. Maj J., Rogoz Z. Pharmacological effects of venlafaxine, a new antidepressant, given repeatedly, on the alpha 1-adrenergic, dopamine and serotonin systems. J. Neural Transm. 106:1999;197-211.
38. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 20:2000;9104-9110.
39. Manier D.H., Gillespie D.D., Sanders-Bush E., Sulser F. The serotonin/noradrenaline-link brain. I. The role of noradrenaline and serotonin in the regulation of density and function of beta adrenoceptors and its alteration by desipramine. Naunyn Schmiedeberg's Arch. Pharmacol. 335:1987;109-114.
40. Martinez D., Hwang D.R., Mawlawi O., Slifstein M., Kent J., Simpson N., Parsey R.V., Hashimoto T., Huang Y., Van Heertun R., Abi-Dorgham A., Caltabiano S., Malizia A., Cowley H., Mann J., Laruelle M. Differential occupancy of somatodendritic and postsynaptic 5-HT(1A) receptors by pindolol: A dose-occupancy study with [11C] way 100635 and position emission tomography in humans. Neuropsychopharmacology. 24:2000;209-229.
41. McGrath C., Norman T.R. The effect of venlafaxine treatment on the behavioural and neurochemical changes in the olfactory bulbectomised rat. Psychopharmacol. (Berlin). 136:1998;394-401.
42. Millan M.J., Gobert A., Rivet J.M., Adhumeau-Auclair A., Cussac D., Newman-Tancredi A., Dekeyne A., Nicolas J.P., Lejeune F. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur. J. Neurosci. 12:2000;1079-1095.
43. Montgomery S.A. Rapid onset of action of venlafaxine. Int.Clin. Psychopharmacol. 10:(Suppl. 2):1995;21-27.
44. Montgomery S., Bech P., Blier P., Moller H.J., Nierenberg A.A., Pinder R.M., Quitkin F.M., Reimitz P.E., Rosenbaum J.F., Rush A.J., Stassen H.H., Thase M.E. Selecting methodologies for the evaluation of differences in time to response between antidepressants. J. Clin. Psychiatry. 63:2002;694-699.
45. Moyer J.A. In vivo antidepressant profiles of the novel bicyclic compounds Wy-45,030 and Wy-454-881 (abstract). Soc. Neurosci. 10:1984;261.
46. Murray C.J., Lopez A.D. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet. 349:1997;1436-1442.
47. Muth E.A., Haskins J.T., Moyer J.A., Husbands G.E., Nielsen S.T., Sigg E.B. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol. 35:1986;4493-4497.
48. Nalepa I., Manier D.H., Gillespie D.D., Rossby S.P., Schmidt D.E., Sulser F. Lack of beta adrenoceptor desensitization in brain following the dual noradrenaline and serotonin reuptake inhibitor venlafaxine. Eur. Neuropsychopharmacol. 8:1998;227-232.
49. Nutt D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatr. Scand. Suppl. 391:1997;31-37.
50. Perez V., Gilaberte E., Faries D., Alvarez E., Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 349:1997;1594-1597.
51. Perez V., Soler J., Puiigdemont D., Alvarez E., Artigas F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch. Gen. Psychiatry. 56:1999;375-379.
52. Perez V., Puiigdemont D., Gilaberte I., Alvarez E., Artigas F. Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. J. Clin. Psychopharmacol. 21:2001;36-45.
53. Porter R.J., McAllister-Williams R.H., Young A.H. Acute effects of venlafaxine and paroxetine on serotonergic transmission in human volunteers. Psychopharmacology (Berlin). 146:1999;194-198.
54. Quitkin F. Onset of action with mirtazapine appears to be more rapid than SSRIs. Int. J. Neuropsychopharmacol. 3:2000;S245.
55. Quitkin F.M., Rabkin J.G., Ross D., Stewart J.W. Identification of true drug response to antidepressants. Use of pattern analysis. Arch. Gen. Psychiatry. 41:1984;782-786.
56. Rabiner E.A., Gunn R.N., Castro M.E., Sargent P.A., Cowen P.J., Koepp M.J., Meyer J.H., Bench C.H., Harrison P.J., Pagos A., Sharp T., Grasby P.M. β-Blocker binding to human 5-HT(1A) receptors in vivo and in vitro: implications for antidepressant therapy. Neuropsychopharmacology. 23:2000;285-293.
57. Rabiner E.A., Bhagwagar Z., Gunn R.N., Sargent P.A., Bench C.J., Cowen P.J., Grasby P.M. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am. J. Psychiatry. 158:2001;2080-2082.
58. Rasanen P., Hakko H., Tiihonen J. Mitchell B. Balter Award: 1998. Pindolol and major affective disorders: a three-year follow-up study of 30,485 patients. J. Clin. Psychopharmacol. 19:1999;297-302.
59. Rogoz Z., Dziedzicka-Wasylewska M., Maj J. Pharmacological profile of venlafaxine, a new antidepressant, given acutely. Pol. J. Pharmacol. 50:1998;107-115.
60. Romero L., Bel N., Artigas F., de Montigny C., Blier P. Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology. 6:1997;91.
61. Rouillon F., Gorwood P. The use of lithium to augment antidepressant medication. J. Clin. Psychiatry. 59:1998;32-39.
62. Schutte A.J., Van Oers H. Survival analysis (Kaplan-Meier; Stassen) and pattern analysis to assess the onset of action in mirtazapine vesus other new antidepressants. Eur. Neuropsychopharmacol. 12:(Suppl. 3):2002;S187.
63. Sheline Y.I., Shanghavi M., Mintun M.A., Gado M.H. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J. Neurosci. 19:1999;5034-5043.
64. Stassen H., Delini-Stula A., Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur. Neuropsychopharmacol. 3:1993;127-135.
65. Szabo S.T., Blier P. Serotonin (1A) receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABA(A) receptors: a microiontophoretic study in the rat locus coeruleus. Synapse. 42:2001;203-212.
66. Szabo S.T., Blier P. Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Res. 922:2001;9-20.
67. Szabo S.T., Blier P. Effects of the selective noradrenergic reuptake blocker reboxetine on the firing activity of locus coeruleus noradrenergic and dorsal raphe serotonin neurons. Eur. J. Neurosci. 13:2001;1-14.
68. Szabo S.T., de Montigny C., Blier P. Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. Br. J. Pharmacol. 126:1999;568-571.
69. Takagi H., Yamamoto K., Shiosaka S., Senba E., Takatsuki K., Inagaki S., Sakanaka M., Tohyama M. Morphological study of noradrenaline innervation in the caudal raphe nuclei with special reference to fine structure. J. Comp. Neurol. 203:1981;15-22.
70. Tome M.B., Isaac M.T., Harte R., Holland C. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int. Clin. Psychopharmacol. 12:1997;81-89.
71. Van Bockstaele E.J. Multiple substrates for serotonergic modulation of rat locus coeruleus neurons and relationships with kainate receptors. Brain Res. Bull. 51:2000;433-442.
72. Van Hensbeek I., Van Oers H., Schutte A.J. Early onset of action of mirtazapine versus other new-generation antidepressants for patients in remission. Eur. Neuropsychopharmacol. 12:(Suppl. 3):2002;S187.
73. Van Oers H., Schutte A.J., Van Hensbeek I. Mirtazapine versus other new-generation antidepressants: pooled analysis on the onset of action. Eur. Neuropsychopharmacol. 12:(Suppl. 3):2002;S187.
74. Vandermaelen C.P., Aghajanian G.K. Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. Brain Res. 289:1983;109-119.
75. Velasco A., Arruza A., Maroto M., Carvajal A., Fernandez del Busto E., Garcia del Pozo J. Effect of venlafaxine hydrochloride in different preparations of isolated guinea-pig and rat organ tissues. J. Auton. Pharmacol. 19:1999;109-113.
76. Vester-Blokland E., Van Oers H. Mirtazapine orally disintegrating tablets versus sertraline: response and remission in a prospective onset-of-action trial. Eur. Neuropsychopharmacol. 12:(Suppl. 3):2002;S186.
77. Wheatley D.P., van Moffaert M., Timmerman L., Kremer C.M. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J. Clin. Psychiatry. 59:1998;306-312.
78. Zanardi R., Artigas F., Franchini L., Sforzini L., Gasperini M., Smeraldi E., Perez J. How long should pindolol be associated with paroxetine to improve the antidepressant response? J. Clin. Psychopharmacol. 17:1997;446-450.
79. Zanardi R., Franchini L., Gaseperini M., Lucca A., Smeraldi E., Perez J. Faster onset of action fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. J. Clin. Psychopharmacol. 18:1998;441-446.
80. Zanardi R., Serretti A., Rossini D., Franchini L., Cusin C., Lattuada E., Dotoli D., Smeraldi E. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol. Psychiatry. 50:2001;323-330.